The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma

BACKGROUND: Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene are present in approximately 50% of melanomas. The selective BRAF inhibitor vemurafenib has demonstrated significant clinical benefits in patients with melanomas harboring the most common...

Descripción completa

Detalles Bibliográficos
Autores principales: Trudel, Stéphanie, Odolczyk, Norbert, Dremaux, Julie, Toffin, Jérôme, Regnier, Aline, Sevestre, Henri, Zielenkiewicz, Piotr, Arnault, Jean-Philippe, Gubler, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192296/
https://www.ncbi.nlm.nih.gov/pubmed/25265970
http://dx.doi.org/10.1186/1471-2407-14-727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192296/
https://www.ncbi.nlm.nih.gov/pubmed/25265970
http://dx.doi.org/10.1186/1471-2407-14-727

Ejemplares similares